Table 4: Secondary Outcomes of two high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 4: Secondary Outcomes of two high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 4: Secondary Outcomes of two high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 4: Secondary Outcomes of two high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 4: Secondary Outcomes of two high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626)
Outcome
Atorvastatin 40mg Users (N= 475) n (%) Atorvastatin 80mg Users (N= 151) n (%) Adjusted Hazard Ratio 95% CI
P-value
Secondary effectiveness endpoints at 1 month
All-cause mortality
0
2 (1.3)
1 (0.03-35.2)
1.0
Cardiovascular mortality
0
2 (1.3)
1 (0.03-35.2)
1.0
Fatal or non-fatal stroke
0
0
Fatal or non-fatal ACS
5 (1.1)
0
1 (0.10-9.60)
1.0
Coronary revascularization
2 (0.4)
0
1 (0.03-37.45)
1.0
Stent thrombosis
0
0
Stent restenosis
0
0
Secondary effectiveness endpoints at 12 months
All-cause mortality
1 (0.2)
1 (0.7)
1 (0.02-41.29)
1.0
Cardiovascular mortality
1 (0.2)
1 (0.7)
1 (0.02-41.29)
1.0
Fatal or non-fatal stroke
4 (0.8)
0
0.577*
Fatal or non-fatal ACS
11 (2.3)
4 (2.6)
0.79 (0.18-3.41)
0.749
Coronary revascularization
5 (1.1)
3 (2.0)
0.62 (0.09-4.31)
0.632
Stent thrombosis
0
0
Stent restenosis
2 (0.4)
1 (0.7)
1 (0.02-66.3)
1.0
Lipid lowering outcomes
LDL-C < 70mg/dLa
114 (24.0)
34 (22.5)
0.812**
Reduction of LDL-C by 50%a
72 (15.2)
32 (21.2)
0.022**
Safety outcomes
Myopathy
4 (0.8)
1 (0.7)
1.0*
ALT > 3 ULN
4 (0.8)
1 (0.7)
1.0*
AST > 3 ULN
3 (0.6)
0
1.0*
Rhabdomyolysis
0
0
Adverse drug event requiring statin discontinuation
3 (0.3)
0
1.0*
*P-value was obtained using Fisher’s Exact test; **P-value was obtained using Chi-square test; aMissing data for ~60% of study participants in both arms; ACS: acute coronary syndrome; LDL-C: low-density lipoproteins cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase *P-value was obtained using Fisher’s Exact test; **P-value was obtained using Chi-square test; aMissing data for ~60% of study participants in both arms; ACS: acute coronary syndrome; LDL-C: low-density lipoproteins cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase *P-value was obtained using Fisher’s Exact test; **P-value was obtained using Chi-square test; aMissing data for ~60% of study participants in both arms; ACS: acute coronary syndrome; LDL-C: low-density lipoproteins cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase *P-value was obtained using Fisher’s Exact test; **P-value was obtained using Chi-square test; aMissing data for ~60% of study participants in both arms; ACS: acute coronary syndrome; LDL-C: low-density lipoproteins cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase *P-value was obtained using Fisher’s Exact test; **P-value was obtained using Chi-square test; aMissing data for ~60% of study participants in both arms; ACS: acute coronary syndrome; LDL-C: low-density lipoproteins cholesterol; ALT: alanine aminotransferase; AST: aspartate aminotransferase